A Very Early Rehabilitation Trial

Stroke Clinical Trial

— AVERT  

Official title:

A Phase 3, Multicentre, Randomised Controlled Trial of Very Early Rehabilitation After Stroke.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01846247
• Other study ID #: version3 25April08
• Secondary ID: ACTRN12606000185
• Status: Completed
• Phase: N/A
• First received: April 30, 2013
• Last updated: April 13, 2015
• Start date: June 2006
• Est. completion date: January 2015

Study information

• Verified date: April 2015
• Source: Neuroscience Trials Australia
• Contact: n/a
• Is FDA regulated: No
• Health authority: Australia: Human Research Ethics CommitteeSingapore: Institutional Review BoardNew Zealand: Institutional Review BoardUnited Kingdom: National Health Service
• Study type: Interventional

Clinical Trial Summary

Phase 3, multicenter, international randomized controlled trial of a Very Early Mobilization(VEM) care rehabilitation protocol compared to standard post stroke care (SC). Participants receive either SC and VEM or SC alone in the acute phase of stroke up to a period of 14 days.

Participants are followed up by a blinded assessor at 3 and 12 months post stroke to determine trial outcomes.

Description:

People who suffer a stroke are often left with disabilities such as weakness, or problems with speech, thinking, or control or bodily functions. Severe strokes often result in death. The results of a recent European study indicated that patients who commence mobility training very early after a stroke (Day 1) recover the ability to walk more quickly and return home sooner and in greater numbers than those who start training one week or later after stroke. Recently a phase II (pilot) AVERT study was conducted in which the investigators tested the safety and feasibility of very early mobilisation (European model) Stroke patients in this study randomly received either standard care or very early mobilisation (VEM). The study showed that there was no harm to patients in the VEM group compared to those who had standard care and that delivering VEM was feasible. Consequently, a grant to conduct the larger phase III study, to test the effectiveness of the intervention was obtained.

In this next phase III trial, the investigators aim to look at 2104 patients across stroke care units in city and regional hospitals. Each hospital will be asked to include between 30 and 60 patients per year to the study. All stroke patients admitted to the hospital Stroke Unit or ward at the hospital will be invited to participate. Medical clearance will be obtained for all potential participants. Those unconscious or too ill, together with those already participating in acute drug trials will be excluded. Patients who are able will provide their own consent to participate. Those who are not able to consent for themselves will have a third party (usually a relative) acknowledge their participation in the study. As this is a blinded controlled trial, keeping the assessor and patients unaware of their treatment group is important. The investigators will inform patients that they will have a 50% chance of receiving one of two rehabilitation types during their hospitalization if they decide to participate. Patients in the VEM group will commence treatment within 24 hours of admission to hospital. VEM will be provided by a trained AVERT physiotherapist, and AVERT study nurse and aims to improve functional mobility. The mobilization activities will depend on the patient's functional ability and tolerance to exercise. Patients will be closely monitored prior to mobilization and will only be mobilised if they meet requirements for blood pressure and other vital signs. The number of sessions and the time spent for each patient will vary, however specific targets are to be met according to the intervention protocol. The content and timing of all treatment received by participants in either group will be recorded. The treatment period for this study is from the time of the patients consent, until day 14 or discharge from the stroke unit or ward. (Whichever is earlier). All participants will be assessed at admission to the study, 3 months, and 12 months after their stroke. Information collected by the AVERT physiotherapists and nurses and the assessor will be recorded on individual case record forms and on a secure web based data base. Therapists also add some information to a palm pilot, and then download it onto the secure website. All information collected from patients will be treated as confidential in line with international guidelines and local law.

The primary outcome measure for the study is the number of patients dead and disabled at 3 months after stroke. Other secondary outcome measures include the safety of patients, quality of life, and cost effectiveness. An independent Data Monitoring committee will monitor the safety, conduct and efficacy of the trial. In addition, an independent outcomes committee will be reviewing all events that are reported as serious.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2014
• Est. completion date: January 2015
• Est. primary completion date: December 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Informed consent

• Clinical diagnosis of first or recurrent stroke, hemorrhage or infarct.

• Recruited within 24 hours of onset of stroke symptoms

• Admission in a stroke care unit

• Consciousness: At a minimum patient must at least react to verbal commands.

Exclusion Criteria:

• pre stroke mRS of 3,4 or 5

• Deterioration in patients condition resulting in direct admission to ICU, decision to palliate or surgery.

• Concurrent diagnosis of rapidly deteriorating disease

• Unstable coronary or other medical condition that is judged by the investigator to impose a hazard to the patient by involvement

• Patients unable to be mobilized within 24 hours of onset. (eg bed rest policy post tPA, lower limb fracture)

• Other interventional trials

• Systolic BP less than 110 or greater than 220mmHg

• Oxygen saturation of less than 92 % with supplementation

• Resting heart rate of less than 40 or greater than 110 beats per minute

• Temperature of greater than 38.5 degrees C

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Stroke

Intervention

Other:
• Standard Care + VEM
Patient will receive standard stroke unit care with earlier and additional physiotherapy and nursing sessions as per an intervention protocol.
• Standard care

Locations

Country	Name	City	State
Australia	Florey Institute for Neuroscience and Mental health	Melbourne	Victoria

Sponsors (6)

Lead Sponsor	Collaborator
Neuroscience Trials Australia	Chest, Heart and Stroke Association Scotland, National Institute for Health Research, United Kingdom, Northern Ireland Chest Heart and Stroke, Singhealth Foundation, The Stroke Association - UK

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	modified Rankin Score	Favorable outcome (0-2) modified Rankin Score	3 months	No
Secondary	Safety. Death rate and severity of important medical events	Important medical events (stroke progression, recurrent stroke, falls, angina, myocardial infarction, deep vein thrombosis, pulmonary emboli, pressure sores, chest infections, urinary tract infections, depression) at 3 months.	up until 3 months	Yes
Secondary	Time to unassisted walking over 50 meters and the proportion achieving unassisted walking	Achieves walking independently or with supervision over 50 meters	3 Months	No
Secondary	modified Rankin Score	Assumption free ordinal approach	3 months	No
Secondary	Health related Quality of life	AQoL	12 months	No
Secondary	Cost effectiveness and cost utility	comprehensive questionaire	12 months	No